Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | PAK4 | O96013 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 16/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501933 | 1.00 | AURKA (0.47) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL5954827 | 0.86 | AURKA (0.54) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL4497871 | 0.86 | AURKA (0.54) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL4510836 | 0.86 | AURKA (0.53) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL4893878 | 0.85 | AURKA (0.49) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL4895796 | 0.84 | AURKA (0.51) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL4501920 | 0.84 | AURKA (0.48) | AURKAAURKBCDK2PAK4FLT3 | |
| SCHEMBL5194410 | 0.83 | AURKA (0.51) | AURKAAURKBFLT3 | |
| SCHEMBL4888262 | 0.82 | AURKA (0.48) | AURKAAURKBCDK2FLT3CHEK1 | |
| SCHEMBL5954692 | 0.81 | FLT3 (0.49) | AURKAAURKBCDK2FLT3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
| EP-2001882-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007107346-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | AURKA 1558/4885AURKB 2087/4885CDK2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.